

Screening and Monitoring for Wilson Disease (WD)

Dr Indra van Mourik
Consultant Paediatric Hepatologist



Paediatric WD

- Most children present with liver disease:
 - Asymptomatic: coincidental finding or family screening
 - Symptomatic - non acute
 - Symptomatic - Acute liver failure
- Neurological and psychiatric symptoms are extremely rare



Diagnostic Tools: similar



Birmingham Women's
and Children's
NHS Foundation Trust

- Overall clinical/biochemical picture – raises suspicion
- Ceruloplasmin levels
- Total serum copper
- Urinary copper excretion/Penicillamine challenge
- Mutation analysis:
 - More than 500 mutations within the *ATP7B* gene
 - Most patients are compound heterozygotes
 - Next-generation sequencing can identify both mutant alleles in 95% of patients (risk is identifying variants of unknown significance)



- Liver biopsy and quantitative copper analysis
 - If molecular testing inconclusive or not available (although we usually end up doing a liver biopsy)
 - Only few studies evaluating diagnostic accuracy of liver copper content in children
 - Liver copper content is increased:
 - In early infancy (physiological)
 - In healthy heterozygotes
 - In chronic cholestatic disease (eg EHBA)
 - Liver histology alone cannot be used to establish a diagnosis of WD



Paediatrics specific Challenges

- The diagnosis of WD is very difficult particularly in young and/or asymptomatic children or in mild disease
- Show atypical or insufficient findings of biochemical and clinical tests for WD:
 - Ceruloplasmin levels:
 - Can be normal
 - Age impact: low in neonates, gradually rises with age with peak in mid childhood, then declines again during puberty
 - Urinary copper excretion:
 - Often normal in asymptomatic children or children with mild liver disease
 - Penicillamine challenge: unreliable to rule out diagnosis in asymptomatic children
 - KF-rings are absent



Family screening

- Genetic counseling is essential
- Screening of first degree relatives
 - Siblings (as early as 2 years of age)
 - Parents
 - Offspring of affected parent, particularly in consanguineous families (Wd in 2 consecutive generations in non-consanguineous families has been reported)
- Physical examination, serum ceruloplasmin, liver function tests,
- molecular genetic testing (mutation analysis or haplotype analysis)



Sibling screening challenges



Birmingham Women's
and Children's
NHS Foundation Trust

- Parental willingness for siblings to be screened – safeguarding issue
- Uncertainty if unusual or no mutations are found in index case
- Screening will only report if WD confirmed in sibling. Labs will not report carrier status or no mutations unless sibling requests results when reaching adulthood



Treatment

- Aim: normal physical examination and normal liver function tests
- Options:
 - removal of copper excess by chelating agents (D-penicillamine or Trientine) or
 - blocking intestinal copper absorption with zinc salts



Monitoring Practice



Birmingham Women's
and Children's
NHS Foundation Trust


Purpose is Two-fold:

- Efficacy & side effects –

- Routine FBC/Biochem/Coag (not copper/ceruloplasmin) at each visit
- proteinuria
- Occasional LBx to watch copper content (never serial)

- Compliance - Practice within our unit varies

- no monitoring
- 24hrs urine collection (zinc/copper): how often and how to interpret
 - Annual monitoring
 - Presymptomatic children excrete less copper c/t symptomatic
 - Different for zinc therapy c/t penicillamine or trientine



Practice Guidelines



Birmingham Women's
and Children's
NHS Foundation Trust

- EASL – Journal of Hepatology 2012 vol.56: 671 – 685
- ESPGHAN – JPGN, Vol 66, Number 2, February 2018



Diagnostic approach to WD (ESPGHAN PG 02/2018)

Step 1

- Clinical evaluation for HSM, KF rings, ascites
- Liver tests: AST/ALT, SBR, INR, AP
- Biochemical tests of copper metabolism: ceruloplasmin, 24hr copper excretion

Step 2

- Molecular testing (common mutations, whole gene sequencing)

Step 3

- Liver copper (if molecular testing inconclusive or unavailable)



ESPGHAN – Ferenci score (consensus 2001) – diagnostic score in WD (adopted for EuroWilson Database)

Score	-1	0	1	2	4
KF rings		Absent		Present	
Neuropsychiatric symptoms		Absent		Present	
Coombs –ve hemol anaemia + high serum copper		Absent	Present		
Urinary copper		Normal	1-2 xULN	> 2x ULN or normal but >5x ULN 1 day after penicillamine challenge	
Quant Liver copper	normal		<5 x ULN	> 5x ULN	
Rhodanine+ve hepatocytes (if no quant Copper available)		Absent	Present		
Serum ceruloplasmin		>0.2 g/L	0.1- 0.2 g/L	<0.1 g/L	
Disease causing mutation detected		None			2

0-1: unlikely 2-3: probable 4 or more: highly likely



King's Wilson index (2005)

Scoring system to predict outcome of children with hepatic decompensation:

Score	SBR ($\mu\text{mol/L}$)	INR	AST	Leuco's, $10^9/\text{L}$	Albumin g/L
0	0-100	0-1.29	0-100	0-6.7	>45
1	101-150	1.3-1.6	101-150	6.8-8.3	34-44
2	151-200	1.7-1.9	151-200	8.4-10.3	25-33
3	201-300	2.0-2.4	201-300	10.4-15.3	21-24
4	>300	>2.5	>300	>15.3	0-20

Score ≥ 11 = urgent listing for transplant



Conclusion

- Similarities in approach to diagnostics, screening and monitoring
- Paediatric specific challenges

